1. Home
  2. DLR vs ARGX Comparison

DLR vs ARGX Comparison

Compare DLR & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Digital Realty Trust Inc.

DLR

Digital Realty Trust Inc.

HOLD

Current Price

$167.67

Market Cap

54.6B

Sector

Real Estate

ML Signal

HOLD

Logo argenx SE

ARGX

argenx SE

HOLD

Current Price

$848.64

Market Cap

50.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DLR
ARGX
Founded
2004
2008
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
54.6B
50.4B
IPO Year
2004
2017

Fundamental Metrics

Financial Performance
Metric
DLR
ARGX
Price
$167.67
$848.64
Analyst Decision
Buy
Strong Buy
Analyst Count
18
19
Target Price
$194.35
$979.22
AVG Volume (30 Days)
1.9M
402.2K
Earning Date
02-05-2026
02-26-2026
Dividend Yield
2.99%
N/A
EPS Growth
240.80
N/A
EPS
3.87
23.27
Revenue
$5,841,036,000.00
$3,683,281,000.00
Revenue This Year
$12.44
$91.44
Revenue Next Year
$10.70
$36.90
P/E Ratio
$42.15
$33.83
Revenue Growth
8.67
92.98
52 Week Low
$129.95
$510.06
52 Week High
$182.48
$934.62

Technical Indicators

Market Signals
Indicator
DLR
ARGX
Relative Strength Index (RSI) 67.32 54.91
Support Level $157.15 $810.52
Resistance Level $165.23 $881.89
Average True Range (ATR) 4.11 21.38
MACD 0.88 7.50
Stochastic Oscillator 95.08 70.10

Price Performance

Historical Comparison
DLR
ARGX

About DLR Digital Realty Trust Inc.

Digital Realty owns and operates over 300 data centers worldwide. It has nearly 40 million rentable square feet across five continents. Digital's offerings range from retail co-location, where an enterprise may rent a single cabinet and rely on Digital to provide all the accommodations, to "cold shells," where hyperscale cloud service providers can simply rent much, or all, of a barren, power-connected building. In recent years, Digital Realty has deemphasized cold shells and now primarily provides higher-level service to tenants that outsource their related IT needs to Digital. The company operates as a real estate investment trust.

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Share on Social Networks: